Asthma therapy - deCODE genetics
Alternative Names: MAP3K9 kinase inhibitors - deCODELatest Information Update: 02 Oct 2021
At a glance
- Originator deCODE genetics
- Class Gene therapies
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 03 May 2006 deCODE has completed a phase II trial in asthma in Iceland
- 18 May 2005 Phase-II clinical trials in Asthma in Iceland (unspecified route)
- 17 Dec 2004 deCODE genetics has formed a drug development agreement with an undisclosed company